Add BrightSurf on Google Email

Science News for November 19, 2010


I2R Known-item-Search technology takes top honors at US standards annual TRECVID conference

The I2R team achieved high performance in both automatic and interactive search categories, showcasing the effectiveness of their Known-item-Search technology. With a mean inverted rank of 0.454 in automatic search and 0.727 in interactive search, they outperformed other teams and demonstrated the potential of their innovation.

COPD could be a problem with autoimmunity

Research suggests moderate to severe COPD may involve an auto-immune component, with 34% of patients having abnormal ANA and AT levels in their blood. The study found a significant association between these auto-antibodies and impairment of lung function.

SourceAmerican Thoracic Society·JournalAmerican Journal of Respiratory and Critical Care Medicine·DateNov 19, 2010

Reading the signs: Plants and animals found common ground in response to microbial threats

Researchers have discovered that plants and animals share remarkably similar mechanisms to detect molecular signatures of infectious organisms, which could lead to new treatments for human diseases. The study's findings highlight the potential for inter-specific transfer of engineered receptors to confer resistance to various pathogens.

Designing more effective anti-HIV antibodies

Researchers at Boston Children's Hospital discovered that some HIV antibodies target the protein in its final form, making them ineffective. The team proposes designing immunogens to trap the protein in an intermediate state, preventing further structural rearrangements and blocking membrane fusion.

SourceBoston Children's Hospital·JournalNature Structural & Molecular Biology·DateNov 19, 2010

New microscope reveals ultrastructure of cells

Researchers have developed a new X-ray microscope that delivers immediate 3D images of entire living cells, closing the gap between conventional microscopic techniques. The new method allows for high-resolution imaging without chemical fixation or labelling, enabling detailed study of cellular ultrastructure.

SourceHelmholtz Association·JournalNature Methods·DateNov 19, 2010

Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting

Phase III trial data suggests Tumor Treating Fields (TTF) therapy increases median survival time and improves quality of life scores compared to standard chemotherapy. Younger patients and those with better functional status show an impressive survival advantage.